In announcing RFK Jr. as having a significant role in healthcare in his administration, he has targeted healthcare in America as a prime candidate for major change.

Robert F. Kennedy Jr. has spent years questioning the federal agencies in charge of vaccine production and safety. Now he is poised to potentially oversee those agencies in a second Trump administration,

Kennedy Jr. is part of President-elect Donald Trump‘s transition team, how should investors think about his potential influence in the healthcare space? Probably with less trepidation than some appear to be feeling,

Peter McCullough, Casey Means, Joel Salatin, and Simone Gold are all getting upvotes on a MAHA nomination site for the Trump administration.

Robert F. Kennedy Jr. has reportedly taken on a role as a hiring manager for top jobs across the U.S government’s health agencies in signs that President-elect Donald Trump has allowed him to “go wild on health” as promised.

"On January 20, the Trump White House will advise all U.S. water systems to remove fluoride from public water. Fluoride is an industrial waste associated with arthritis, bone fractures, bone cancer, IQ loss, neurodevelopmental disorders, and thyroid disease," Kennedy said on social media over the weekend.

RFK Jr. has said Trump promised him “control of the public health agencies,” including the National Institutes of Health and the Centers for Disease Control and Prevention. He’s talked about cleaning up “corruption” at those agencies and reorienting them towards a chronic disease focus (in a page on his MAHA website that has since been scrubbed).

Not much is known about what role Kennedy could actually serve in the second Trump administration. Here's some of what we do know.

A doctor fears that an RFK Jr.-influenced Trump White House will discourage vaccination and block the release of data showing the disastrous consequences.